It has previously been demonstrated that topical nasal treatment with
glucocorticosteroids has significant effects on the bronchial airways,
Less is known about effects on nasal disease by topical bronchial tre
atment with these drugs, The present study examined effects on nasal a
llergic disease of inhaled budesonide (avoiding nasal deposition of th
e drug). Patients with seasonal allergic rhinitis, but without asthma,
were thus given inhalations of budesonide (600 mu g b.i.a) or placebo
. The aim of the design was to allow the study of eosinophilic airway
disease in a part of the airway other than the directly treated locus.
Moderate to high birch pollen levels were recorded during the study s
eason, and nasal symptoms were significantly increased in both treatme
nt groups, although they were milder in patients receiving budesonide
than in the placebo group (p<0.05). Nasal brush eosinophils and nasal
lavage fluid levels of eosinophil cationic protein as well as blood eo
sinophils were increased during the season (p<0.05), but these increas
es were prevented by the inhaled budesonide. Nasal lavage fluid levels
of alpha(2)-macroglobulin were particularly elevated in the placebo g
roup but did not differ between patients receiving placebo and budeson
ide, Budesonide prevented the seasonal development of increased bronch
oconstrictor responses to methacholine challenge (p<0.05). In conclusi
on, budesonide reduced the seasonal eosinophilia both in the circulati
on and in the nose along with an attenuation of seasonal nasal symptom
s, Hence, at a daily dose of 600 mu g b.i.d., known to cause no, or mi
nimal, adverse effects, inhaled budesonide produces clinically signifi
cant anti-inflammatory effects in the entire airways, including the na
sal mucose, which is not exposed topically to the drug, We suggest tha
t nasal and systemic anti-eosinophil actions are produced at commonly
employed dose levels of orally inhaled budesonide.